Drugs / TAK-105-a
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04964258 | Jul 2021 → Jun 2023 | — | Takeda | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-105-a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04964258 ↗ |
| Known as | TAK-105 | “The drug being tested in this study is called TAK-105.” NCT04964258 ↗ |
| Route | Subcutaneous | “injection under the skin (sub-cutaneous injection)” NCT04964258 ↗ |